Physician profile
Jonathan E Fisher
NPI 1508872995
$1,854.01
in general payments reported to CMS, 2019-2025
21 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.92 · 2021: $144 · 2022: $417 · 2023: $431 · 2024: $384 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082 · Grant: $147 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.46 |
| Grant | $147.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $399.80 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $265.05 | 2022-2025 | |
| Boston Scientific Corporation | $167.85 | 2022-2025 | Farapulse |
| Inari Medical, INC. | $161.10 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.68 | 2023-2024 | Lifevest |
| Pfizer INC. | $124.47 | 2021-2025 | |
| Abbott Laboratories | $85.72 | 2019-2023 | Mitraclip |
| Novo Nordisk INC | $82.90 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $81.07 | 2019-2025 | Repatha, Repatha |
| Cvrx, INC. | $48.39 | 2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $44.79 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $39.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.41 | 2024-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.70 | 2024-2025 | Jardiance |
| Tactile Systems Technology INC | $28.94 | 2021-2023 | Flexitouch Plus, Entre Plus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $27.47 | 2024 | |
| Abiomed | $25.88 | 2025 | |
| Heartflow, INC. | $23.50 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.92 | 2025 | Wainua |
| Merck Sharp & Dohme LLC | $15.41 | 2024 | Verquvo |
| Bardy Diagnostics, INC. | $4.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.